Endometrial Carcinoma — Trials

Endometrial Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

325 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 109
Recruiting: 52
Ph III recruiting: 4
Growth YoY: —
Industry share: 19%
Top sponsor: National Cancer Institute (NCI)
Termination share: 26.5%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (31)

clinicaltrialsPublishedShowing 51–100 of 139 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03914612	Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer	active not recruiting	Phase 3	813	National Cancer Institute (NCI)NIH	5	Jul 31, 2026	clinicaltrials
NCT04491942	Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer	active not recruiting	Phase 1	74	National Cancer Institute (NCI)NIH